The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kite/Gilead
Stock and Other Ownership Interests - Gilead Sciences
 
Stock and Other Ownership Interests - Celgene
Honoraria - Hexal; Novartis; RIEMSER; Takeda
Consulting or Advisory Role - Kite/Gilead; Novartis; RIEMSER; Takeda
Travel, Accommodations, Expenses - Hexal; Kite/Gilead; Novartis; RIEMSER; Takeda
 
Consulting or Advisory Role - Bayer; Kite/Gilead; Novartis
Speakers' Bureau - Bayer; Kite/Gilead
Research Funding - Celgene; Juno Therapeutics; Kite/Gilead; Seagen
ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).
 
Olalekan O. Oluwole
Consulting or Advisory Role - Kite/Gilead
 
Michael Russell Bishop
Employment - UnitedHealthcare
Honoraria - Celgene
Consulting or Advisory Role - Seagen
Speakers' Bureau - Celgene; Juno Therapeutics; Novartis
 
Christian Gisselbrecht
Research Funding - Roche
 
Leo I. Gordon
Patents, Royalties, Other Intellectual Property - Zylem
Other Relationship - Gilead Sciences
 
Marie Jose Kersten
Honoraria - Amgen; BMS Brazil; Celgene; Gilead Sciences; Kite/Gilead; MSD; Mundipharma; Novartis; Roche; Takeda
Research Funding - Celgene; Roche; Takeda
 
David G. Maloney
Honoraria - Bristol-Myers Squibb; Celgene; Gilead Sciences; ImmunoGen; Kite, a Gilead company; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; ImmunoGen; Kite, a Gilead company; Roche
Research Funding - Juno Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Juno Therapeutics (Inst)
 
Norbert Schmitz
No Relationships to Disclose
 
María Dolores Caballero Barrigon
No Relationships to Disclose
 
John Kuruvilla
Consulting or Advisory Role - AbbVie; Bristol-Myers Squibb; Merck; Seagen
Research Funding - Janssen; Roche
 
Kevin W. Song
Honoraria - Amgen; Celgene; Gilead Sciences; Janssen; Takeda
Consulting or Advisory Role - Amgen; Celgene; Gilead Sciences; Janssen; Takeda
Research Funding - Amgen; Celgene; Janssen; Kite/Gilead; Takeda
Travel, Accommodations, Expenses - Janssen
 
Caron A. Jacobson
Consulting or Advisory Role - Bayer; Kite/Gilead; Pfizer; Pharmacyclics
Speakers' Bureau - Cowen
 
Loretta J. Nastoupil
Honoraria - Abbvie; Celgene; Genentech/Roche; Gilead Sciences; Novartis; Pharmacyclics; TG Therapeutics
Research Funding - Abbvie; Celgene; Genentech/Roche; Janssen Biotech; Karus Therapeutics; TG Therapeutics
 
Peter Riedell
No Relationships to Disclose
 
Yizhou Jiang
Employment - Kite/Gilead
Stock and Other Ownership Interests - Gilead Sciences
 
John M. Rossi
No Relationships to Disclose
 
Lillian Lee
Employment - Kite/Gilead
Stock and Other Ownership Interests - Gilead Sciences
 
Paul C. Cheng
Employment - Kite/Gilead
Stock and Other Ownership Interests - Gilead Sciences
 
Frederick Lundry Locke
Honoraria - Kite/Gilead
Consulting or Advisory Role - Cellular Biomedicine Group
Research Funding - FORMA Therapeutics; Kite/Gilead
Patents, Royalties, Other Intellectual Property - Survivin Vaccine Patent (Inst)